Genomic Precision to Guide Pre‑Operative Decisions—In Just 6 Days*
MammaPrint + BluePrint identify patients most likely to achieve nodal downstaging and can potentially avoid more invasive surgical procedures.
MammaPrint + BluePrint identify patients most likely to achieve nodal downstaging and can potentially avoid more invasive surgical procedures.
- In the MINT study, 50.5% of patients with LN+, MammaPrint High Risk breast cancer achieved nodal complete response
- BluePrint predicted nodal downstaging with highest nodal complete response rates observed for HER2-Type (73.7%) and Basal-Type (53.7%)
- Nodal downstaging rates for BluePrint HER2-Type and Basal-Type were same regardless of ER status
Blumencranz et al. 2023. Annals of Surgical Oncology
MammaPrint + BluePrint predict sensitivity to NCT in HR+/HER2- early breast cancer
MammaPrint + BluePrint predict sensitivity to NCT in HR+/HER2- early breast cancer
- MammaPrint High Risk 2 identifies HR+/HER2- cancers with higher sensitivity to NCT, which may enable downstaging and may improve overall outcomes
- Patients with MammaPrint High Risk 2 tumors, including Luminal B and Basal subtypes, are more likely to have PR or pCR with NCT, compared to Low Risk and High Risk 1 patients
- MammaPrint + BluePrint identify those Low Risk Luminal A patients who do not benefit from NCT and can avoid overtreatment
O’Shaughnessy et al., SABCS 2024
Discuss the data with your local Agendia MOS & MSL
Request Data Review / Additional Data:
